palonosetron Aloxi
Selected indexed studies
- Palonosetron. (Drugs, 2004) [PMID:15139789]
- Fosrolapitant/Palonosetron: First Approval. (Drugs, 2025) [PMID:40991189]
- Palonosetron (Helsinn). (Curr Opin Investig Drugs, 2002) [PMID:12431027]
_Worker-drafted node — pending editorial review._
Connections
palonosetron Aloxi is a side effect of
Sources
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. (2021) pubmed
- Palonosetron. (2004) pubmed
- Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2020) pubmed
- Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy: A Phase 3 Randomized Clinical Trial. (2024) pubmed
- Fosrolapitant/Palonosetron: First Approval. (2025) pubmed
- Palonosetron (Helsinn). (2002) pubmed
- Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT. (2025) pubmed
- [Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist]. (2010) pubmed
- Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy. (2004) pubmed
- Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. (2009) pubmed